PK101 / PMG Pharm - LARVOL DELTA

Comparison of a fixed-dose combination of Celecoxib/PG201 [Layla®] versus co-administration of individual formulations in healthy participants: A randomized trial. (PubMed, Medicine (Baltimore)) - "The systemic exposure and safety profiles of the individual and FDC formulations were similar, supporting their potential as an innovative and effective therapeutic approach for OA treatment. All relevant data are within the paper and its Supporting Information files."

Clinical • Journal • Cardiovascular • Gastrointestinal Disorder • Immunology • Osteoarthritis • Pain • Rheumatology

A Phase 3 Study to Assess the Efficacy and Safety of PK101 in Patients With Knee Osteoarthritis (clinicaltrials.gov) - P3; N=354; Recruiting; Sponsor: PMG Pharm Co., Ltd; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Immunology • Osteoarthritis • Pain • Rheumatology

A Phase 3 Study to Assess the Efficacy and Safety of PK101 in Patients With Knee Osteoarthritis (clinicaltrials.gov) - P3; N=354; Not yet recruiting; Sponsor: PMG Pharm Co., Ltd

Clinical • New P3 trial • Immunology • Osteoarthritis • Pain • Rheumatology